PolyActiva

PolyActiva is a clinical-stage ophthalmology company that specializes in drug delivery from medical devices. The company was founded in 2009 and is headquartered in Australia. PolyActiva stands out with its unique proprietary polymeric prodrug technology which enables precise and controlled drug delivery specifically to the eye. The technology allows for exceptional zero-order release profiles over extended periods, typically ranging from 6 to 12 months.

With a recent Series B investment of $9.53M in February 2013, PolyActiva garnered funding from notable investors including Yuuwa Capital, Brandon Capital, and the Medical Research Commercialisation Fund (MRCF). The company's mission is to establish itself as a leader in ophthalmic medicine by providing biodegradable implants with sustained drug delivery, ultimately aiming to improve patient outcomes and quality of life.

Overall, PolyActiva's innovative approach to ophthalmic drug delivery presents significant potential for addressing unmet medical needs in the field, with the recent investment underscoring confidence in the company's trajectory and technological capabilities.